Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.64 |
| ▸ | CA1 | P00915 | 5/20 | 0.64 |
| ▸ | CA2 | P00918 | 5/20 | 0.64 |
| ▸ | CA7 | P43166 | 5/20 | 0.64 |
| ▸ | CA9 | Q16790 | 5/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.64 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21079187 | 0.88 | KDM4E (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9005554 | 0.88 | HSD17B2 (0.70) | CA12CA1CA2CA7CA9 | |
| SCHEMBL18789684 | 0.87 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16605589 | 0.86 | MAPT (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7093941 | 0.84 | ALDH1A1 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16605593 | 0.84 | MAPT (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7684319 | 0.84 | MAPT (0.77) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1990526 | 0.83 | CA12 (0.70) | CA12CA1CA2CA7CA9 | |
| SCHEMBL460455 | 0.83 | HSD17B2 (0.77) | CA12CA1CA2CA7CA9 | |
| SCHEMBL23876967 | 0.81 | ALDH1A1 (0.59) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192886-B2 | S1P1 agonist and application thereof | MEDSHINE DISCOVERY INC. (CN) | 2021-12-07 | — | — | US | disclosed |
| US-20210300908-A1 | S1P1 AGONIST AND APPLICATION THEREOF | Shijiazhuang Sagacity New Drug Development Co., Ltd. (CN) | 2021-09-30 | — | — | US | disclosed |
| US-7067665-B2 | Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-06-27 | — | — | US | disclosed |
| US-6953857-B2 | Oxybenzamide derivatives useful for inhibiting factor Xa or viia | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-10-11 | — | — | US | disclosed |
| US-20050165058-A1 | Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-07-28 | — | — | US | disclosed |
| EP-1349847-B1 | OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS | AVENTIS PHARMA GMBH (DE) | 2005-04-20 | — | — | EP | disclosed |
| EP-1135360-B1 | NOVEL 3-ALKOXYBENZYLAMINE DERIVATIVES AND THEIR USE AS MEDICINES FOR TREATING SCHIZOPHRENIA | PF MEDICAMENT (FR) | 2004-03-31 | — | — | EP | disclosed |
| CN-1481376-A | HYDROXYBENZAMIDE DERIVATIVES AS FACTOR XA INHIBITORS | ���ĵ�˹ҩ��¹�����˾ | 2004-03-10 | — | — | CN | disclosed |
| EP-1349847-A1 | OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2003-10-08 | — | — | EP | disclosed |
| US-20020198195-A1 | New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-12-26 | — | — | US | disclosed |
| WO-2002051831-A1 | OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-07-04 | — | — | WO | disclosed |
| US-6350913-B1 | AROMATIC AMINE COMPOUNDS | PIERRE FABRE MEDICAMENT (FR) | 2002-02-26 | — | — | US | disclosed |
| US-5385917-A | Treating androgen dependent diseases | MITSUBISHI KASEI CORPORATION (JP) | 1995-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192886-B2 | S1P1 agonist and application thereof | S1PR1, S1PR2, S1PR3 | CA12 3842/4885CA1 3821/4885CA2 1992/4885 |
| US-20050165058-A1 | Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla | F12, F11, F5 | CA12 4228/4885CA1 4414/4885CA2 3163/4885 |
| US-20020198195-A1 | New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa | F9, F11, F5 | CA12 3684/4885CA1 4325/4885CA2 2450/4885 |
| US-20210300908-A1 | S1P1 AGONIST AND APPLICATION THEREOF | S1PR1, S1PR2, S1PR3 | CA12 3842/4885CA1 3821/4885CA2 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.